Methodological Considerations in ICI-Myositis Research: Immortal Time Bias and Diagnostic Standardization.
Methodological Considerations in ICI-Myositis Research: Immortal Time Bias and Diagnostic Standardization. Arthritis Care Res (Hoboken). 2026 Sep 13.
PMID: 42733231
Management of toxicities due to immune checkpoint inhibitors.
Management of toxicities due to immune checkpoint inhibitors. Clin Adv Hematol Oncol. 2026 Jul-Aug; 24(5):324-327.
PMID: 42550817
Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study.
Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study. J Immunother Cancer. 2026 May 28; 14(5).
PMID: 42208976
The management of rheumatic immune related adverse events.
The management of rheumatic immune related adverse events. Best Pract Res Clin Rheumatol. 2026 Mar; 40(1):102147.
PMID: 42086376
Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study.
Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study. Ann Rheum Dis. 2026 Sep; 85(9):1879-1889.
PMID: 41966859
Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis.
Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2025 12; 77(12):1487-1492.
PMID: 40865544
Real-World Analysis of Patient Characteristics, Adverse Events, and Economic Burden Among Patients with Giant Cell Arteritis Treated with Glucocorticoids.
Real-World Analysis of Patient Characteristics, Adverse Events, and Economic Burden Among Patients with Giant Cell Arteritis Treated with Glucocorticoids. Rheumatol Ther. 2025 Oct; 12(5):835-854.
PMID: 40613868
Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis.
Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis. Rheumatology (Oxford). 2025 06 01; 64(6):3434-3443.
PMID: 39936579
Impact of steroid-sparing immunosuppressive agents on tumor outcome in the context of cancer immunotherapy with highlight on melanoma: a systematic literature review and meta-analysis.
Impact of steroid-sparing immunosuppressive agents on tumor outcome in the context of cancer immunotherapy with highlight on melanoma: a systematic literature review and meta-analysis. Front Immunol. 2024; 15:1499478.
PMID: 39737191
Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk.
Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk. JAMA Netw Open. 2024 11 04; 7(11):e2446336.
PMID: 39565623